|
|
肺鳞癌免疫治疗进展
|
Abstract:
肺癌是世界发病率及死亡率第一的恶性肿瘤，肺鳞癌(Lung squamous cell carcinoma)作为一种常见的病理学类型，约占NSCLC总数的30%。肺鳞癌因其独特的组织学特征，与肺腺癌有显著的不同，其驱动基因突变罕见，因而缺乏有效的靶向治疗。近年来，PD-1/PD-L1抑制剂和细胞周期蛋白依赖性激酶4和6抑制剂(CTLA-4/6)等新药物在肺鳞癌患者中进行了多项临床研究，明显改善了肺鳞癌病人的生存期。本文旨免疫靶向治疗方面描述近几年来肺鳞癌的免疫治疗进展。
Lung cancer is the world’s most common malignant tumor with morbidity and mortality. As a common pathological type, lung squamous cell carcinoma accounts for about 30% of the total number of NSCLC. Lung squamous cell carcinoma is significantly different from lung adenocarcinoma due to its unique histological characteristics. Kinetic gene mutations are rare, so there is a lack of effective targeted therapy. In recent years, new drugs such as PD-1/PD-L1 inhibitors and cyclin dependent kinase 4 and 6 inhibitors (CTLA-4/6) have been studied in patients with lung squamous cell carcinoma, which significantly improved survival in patients. This article aims to describe the progress of immunotherapy for lung squamous cell carcinoma in recent years in terms of targeted immunotherapy.
| [1] | Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492 |
| [2] | Houston, K.A., Henley, S.J., Li, J., White, M.C. and Richards, T.B. (2014) Patterns in Lung Cancer Incidence Rates and Trends by Histologic Type in the United States, 2004-2009. Lung Cancer, 86, 22-28.
https://doi.org/10.1016/j.lungcan.2014.08.001 |
| [3] | Leonetti, A., Sharma, S., Minari, R., Perego, P., Giovannetti, E. and Tiseo, M. (2019) Resistance Mechanisms to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer. British Journal of Cancer, 121, 725-737.
https://doi.org/10.1038/s41416-019-0573-8 |
| [4] | Wang, J., Shen, Q., Shi, Q., et al. (2014) Detection of ALK Protein Expression in Lung Squamous Cell Carcinomas by Immunohistochemistry. Journal of Experimental & Clinical Cancer Research, 33, 109.
https://doi.org/10.1186/s13046-014-0109-2 |
| [5] | Forbes, S.A., Bhamra, G., Bamford, S., et al. (2008) The Catalogue of Somatic Mutations in Cancer (COSMIC). Current Protocols in Human Genetics, Chapter 10, Unit-10.11. |
| [6] | Hirsh, V., Wan, Y., Lin, F.J., et al. (2018) Quality-Adjusted Outcomes Stratified by Response in Patients with Advanced Non-Small-Cell Lung Cancer Receiving First-Line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin. Clinical Lung Cancer, 19, 401-409.e4. https://doi.org/10.1016/j.cllc.2018.04.023 |
| [7] | Wu, X., Gu, Z., Chen, Y., et al. (2019) Application of PD-1 Blockade in Cancer Immunotherapy. Computational and Structural Biotechnology Journal, 17, 661-674. https://doi.org/10.1016/j.csbj.2019.03.006 |
| [8] | Cooper, W.A., Tran, T., Vilain, R.E., et al. (2015) PD-L1 Expression Is a Favorable Prognostic Factor in Early Stage Non-Small Cell Carcinoma. Lung Cancer, 89, 181-188. https://doi.org/10.1016/j.lungcan.2015.05.007 |
| [9] | Efremova, M., Rieder, D., Klepsch, V., et al. (2018) Targeting Immune Checkpoints Potentiates Immunoediting and Changes the Dynamics of Tumor Evolution. Nature Communications, 9, 32.
https://doi.org/10.1038/s41467-017-02424-0 |
| [10] | Brahmer, J., Reckamp, K.L., Baas, P., et al. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 373, 123-135.
https://doi.org/10.1056/NEJMoa1504627 |
| [11] | Wu, Y.L., Lu, S., Cheng, Y., et al. (2019) Nivolumab versus Docetaxel in a Predominantly Chinese Patient Population with Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. Journal of Thoracic Oncology, 14, 867-875. https://doi.org/10.1016/j.jtho.2019.01.006 |
| [12] | Hellmann, M.D., Paz-Ares, L., Bernabe Caro, R., et al. (2019) Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 381, 2020-2031. https://doi.org/10.1056/NEJMoa1910231 |
| [13] | Paz-Ares, L., Ciuleanu, T.E., Cobo, M., et al. (2021) First-Line Nivolumab plus Ipilimumab Combined with Two Cycles of Chemotherapy in Patients with Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 22, 198-211. https://doi.org/10.1016/S1470-2045(20)30641-0 |
| [14] | Herbst, R.S., Baas, P., Kim, D.W., et al. (2016) Pembrolizumab versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial. The Lancet, 387, 1540-1550.
https://doi.org/10.1016/S0140-6736(15)01281-7 |
| [15] | Reck, M., Rodríguez-Abreu, D., Robinson, A.G., et al. (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 375, 1823-1833.
https://doi.org/10.1056/NEJMoa1606774 |
| [16] | Mok, T.S.K., Wu, Y.L., Kudaba, I., et al. (2019) Pembrolizumab versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. The Lancet, 393, 1819-1830. https://doi.org/10.1016/S0140-6736(18)32409-7 |
| [17] | Paz-Ares, L., Luft, A., Vicente, D., et al. (2018) Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 379, 2040-2051. https://doi.org/10.1056/NEJMoa1810865 |
| [18] | Fehrenbacher, L., Spira, A., Ballinger, M., et al. (2016) Atezolizumab versus Docetaxel for Patients with Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial. The Lancet, 387, 1837-1846. https://doi.org/10.1016/S0140-6736(16)00587-0 |
| [19] | Rittmeyer, A., Barlesi, F., Waterkamp, D., et al. (2017) Atezolizumab versus Docetaxel in Patients with Previously Treated Non-Small-Cell Lung Cancer (OAK): A Phase 3, Open-Label, Multicentre Randomised Controlled Trial. The Lancet, 389, 255-265. https://doi.org/10.1016/S0140-6736(16)32517-X |
| [20] | Gandara, D.R., von Pawel, J., Mazieres, J., et al. (2018) Atezolizumab Treatment beyond Progression in Advanced NSCLC: Results from the Randomized, Phase III OAK Study. Journal of Thoracic Oncology, 13, 1906-1918.
https://doi.org/10.1016/j.jtho.2018.08.2027 |
| [21] | Jotte, R., Cappuzzo, F., Vynnychenko, I., et al. (2020) Atezolizumab in Combination with Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results from a Randomized Phase III Trial. Journal of Thoracic Oncology, 15, 1351-1360. https://doi.org/10.1016/j.jtho.2020.03.028 |
| [22] | Rizvi, N.A., Cho, B.C., Reinmuth, N., et al. (2020) Durvalumab with or without Tremelimumab vs Standard Chemotherapy in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial. JAMA Oncology, 6, 661-674. https://doi.org/10.1001/jamaoncol.2020.0237 |
| [23] | Govindan, R., Szczesna, A., Ahn, M.J., et al. (2017) Phase III Trial of Ipilimumab Combined with Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 35, 3449-3457.
https://doi.org/10.1200/JCO.2016.71.7629 |
| [24] | Coletti, A., Greco, F.A., Dolciami, D., et al. (2017) Advances in Indoleamine 2,3-Dioxygenase 1 Medicinal Chemistry. MedChemComm, 8, 1378-1392. https://doi.org/10.1039/C7MD00109F |
